Most importantly, ASB-CLL patients had significantly worse overall survival (log-rank test, p < 0.0088; Fig. 6d) and this was independent of the risk associated with TP53 aberrations (del(17)(p13) or TP53 mutations) and unmutated IGHV genes (Fig. 6e, f). The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.